266 related articles for article (PubMed ID: 35582527)
1. Drug resistance and minimal residual disease in multiple myeloma.
Gozzetti A; Ciofini S; Sicuranza A; Pacelli P; Raspadori D; Cencini E; Tocci D; Bocchia M
Cancer Drug Resist; 2022; 5(1):171-183. PubMed ID: 35582527
[TBL] [Abstract][Full Text] [Related]
2. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.
Mina R; Oliva S; Boccadoro M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32645952
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.
Ferla V; Antonini E; Perini T; Farina F; Masottini S; Malato S; Marktel S; Lupo Stanghellini MT; Tresoldi C; Ciceri F; Marcatti M
Front Oncol; 2022; 12():932852. PubMed ID: 36052251
[TBL] [Abstract][Full Text] [Related]
4. Advances in minimal residual disease monitoring in multiple myeloma.
Wijnands C; Noori S; Donk NWCJV; VanDuijn MM; Jacobs JFM
Crit Rev Clin Lab Sci; 2023 Nov; 60(7):518-534. PubMed ID: 37232394
[TBL] [Abstract][Full Text] [Related]
5. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
7. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
10. Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma.
Oliva S; D'Agostino M; Boccadoro M; Larocca A
Front Oncol; 2020; 10():1. PubMed ID: 32076595
[TBL] [Abstract][Full Text] [Related]
11. Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity.
Suzuki K; Nishiwaki K; Yano S
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638353
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic significance of sequencing-based MRD detection in multiple myeloma].
Takamatsu H
Rinsho Ketsueki; 2015 Aug; 56(8):989-96. PubMed ID: 26345557
[TBL] [Abstract][Full Text] [Related]
13. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
14. Boosting Immunity against Multiple Myeloma.
Lopes R; Ferreira BV; Caetano J; Barahona F; Carneiro EA; João C
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799565
[TBL] [Abstract][Full Text] [Related]
15. New criteria for response assessment: role of minimal residual disease in multiple myeloma.
Paiva B; van Dongen JJ; Orfao A
Blood; 2015 May; 125(20):3059-68. PubMed ID: 25838346
[TBL] [Abstract][Full Text] [Related]
16. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
17. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
18. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.
Landgren O; Iskander K
J Intern Med; 2017 Apr; 281(4):365-382. PubMed ID: 28205262
[TBL] [Abstract][Full Text] [Related]
19. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N; Kim-Schulze S; Parekh S
Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
[TBL] [Abstract][Full Text] [Related]
20. [Methods and clinical values for minimal residual disease detection in patients with multiple myeloma].
Takamatsu H
Rinsho Ketsueki; 2018; 59(10):2153-2161. PubMed ID: 30305521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
